The Ras/Raf/MAPK pathway

被引：256

作者：

Molina, Julian R. ^{[1
]}

Adjei, Alex A. ^{[1
]}

机构：

[1] Mayo Clin, Div Med Oncol, Rochester, MN 55905 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2006年 / 1卷 / 01期

关键词：

D O I：

10.1097/01243894-200601000-00004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：7 / 9

页数：3

共 25 条

[1] Blocking oncogenic Ras signaling for cancer therapy [J].

Adjei, AA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (14) :1062-1074

[2] Ras activation of the Raf kinase: Tyrosine kinase recruitment of the MAP kinase cascade [J].

Avruch, J ;

Khokhlatchev, A ;

Kyriakis, JM ;

Luo, ZJ ;

Tzivion, G ;

Vavvas, D ;

Zhang, XF .

RECENT PROGRESS IN HORMONE RESEARCH, VOL 56, 2001, 56 :127-155

[3] RAS GENES [J].

BARBACID, M .

ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 :779-827

[4] THE EPIDERMAL GROWTH-FACTOR [J].

BOONSTRA, J ;

RIJKEN, P ;

HUMBEL, B ;

CREMERS, F ;

VERKLEIJ, A ;

HENEGOUWEN, PVE .

CELL BIOLOGY INTERNATIONAL, 1995, 19 (05) :413-430

[5] GTPases and T cell activation [J].

Cantrell, DA .

IMMUNOLOGICAL REVIEWS, 2003, 192 (01) :122-130

[6]

Cary LA, 1999, HISTOL HISTOPATHOL, V14, P1001, DOI 10.14670/HH-14.1001

[7] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[8]

Dergham ST, 1997, INT J PANCREATOL, V21, P127

[9] Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].

Eberhard, DA ;

Johnson, BE ;

Amler, LC ;

Goddard, AD ;

Heldens, SL ;

Herbst, RS ;

Ince, WL ;

Jänne, PA ;

Januario, T ;

Johnson, DH ;

Klein, P ;

Miller, VA ;

Ostland, MA ;

Ramies, DA ;

Sebisanovic, D ;

Stinson, JA ;

Zhang, YR ;

Seshagiri, S ;

Hillan, KJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909

[10] High frequency of Ki-ras amplification and p53 gene mutations in adenocarcinomas of the human esophagus [J].

Galiana, C ;

Lozano, JC ;

Bancel, B ;

Nakazawa, H ;

Yamasaki, H .

MOLECULAR CARCINOGENESIS, 1995, 14 (04) :286-293

← 1 2 3 →